Acadia Pharmaceuticals Inc (NASDAQ:ACAD) currently has a daily average trading volume of 2.12M but it saw 2621838 shares traded in last market. With a market cap of 3.66B USD, the company’s current market price of $21.85 came rising about 0.74 while comparing to the previous closing price of $21.69. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.23 and as low as $13.40.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Deutsche Bank which upgraded the stock as “Buy” in its note to investors issued on May 21, 2025, recommending a price target of $35 for it. Guggenheim issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $23 and $20.
Over the week, ACAD’s stock price is moving 27.33% up while it is 52.26% when we observe its performance for the past one month. Year-to-date it is 19.07% up and over the past year, the stock is showing an upside performance of 47.73%.
Currently, Acadia Pharmaceuticals Inc’s total number of outstanding shares is 167.12M with 0.66% of that held by the insiders while 105.71% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 28.26% and return on equity (ROE) at 37.24%. It has a price to earnings ratio (P/E ratio) of 15.91 while having a 25.50 of forward P/E ratio. Stock’s beta reads 0.61. Stock has a price to book (P/B) ratio of 4.77 while price to sale or P/S ratio amounts to 3.67. Its return on asset (ROA) is 23.03% on average.
